Positive News SentimentPositive NewsNASDAQ:ANAB AnaptysBio (ANAB) Stock Forecast, Price & News $17.96 -0.04 (-0.22%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$17.43▼$18.0950-Day Range$16.74▼$20.5652-Week Range$16.51▼$32.44Volume182,012 shsAverage Volume291,710 shsMarket Capitalization$476.84 millionP/E RatioN/ADividend YieldN/APrice Target$34.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AnaptysBio MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside93.5% Upside$34.75 Price TargetShort InterestBearish20.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.80Based on 2 Articles This WeekInsider TradingSelling Shares$116,257 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($6.61) to ($6.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector872nd out of 972 stocksPharmaceutical Preparations Industry411th out of 449 stocks 3.2 Analyst's Opinion Consensus RatingAnaptysBio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.75, AnaptysBio has a forecasted upside of 93.5% from its current price of $17.96.Amount of Analyst CoverageAnaptysBio has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.15% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 1.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANAB. Previous Next 3.2 News and Social Media Coverage News SentimentAnaptysBio has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AnaptysBio this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,257.00 in company stock.Percentage Held by Insiders35.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AnaptysBio are expected to decrease in the coming year, from ($6.61) to ($6.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AnaptysBio (NASDAQ:ANAB) StockAnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Read More ANAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANAB Stock News HeadlinesSeptember 25, 2023 | marketbeat.comArgenx's 28% Surge & Promising Product Propel Investor Confidence (ANAB)Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.September 23, 2023 | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Hold" by BrokeragesOctober 1, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 19, 2023 | finance.yahoo.comInsider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio IncSeptember 14, 2023 | benzinga.comAnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual SummitAugust 8, 2023 | msn.comWedbush Maintains AnaptysBio (ANAB) Neutral RecommendationAugust 8, 2023 | benzinga.comAnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business UpdateJuly 31, 2023 | marketwatch.comAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.October 1, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.July 7, 2023 | seekingalpha.comAnaptysBio: Despite Early Successes, Current Situation Does Not ImpressJuly 6, 2023 | msn.comAnaptysBio (ANAB) Price Target Increased by 6.91% to 33.15July 4, 2023 | finance.yahoo.comShareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years agoMay 31, 2023 | fool.comAnaptysBio (NASDAQ: ANAB)May 30, 2023 | finance.yahoo.comAnaptysBio Announces Participation in Upcoming Investor ConferencesMay 24, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023May 22, 2023 | msn.comJP Morgan Upgrades AnaptysBio (ANAB)May 20, 2023 | finance.yahoo.comWall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should KnowMay 18, 2023 | msn.comAnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agentsMay 13, 2023 | msn.comGuggenheim Maintains AnaptysBio (ANAB) Buy RecommendationMay 13, 2023 | msn.comWedbush Reiterates AnaptysBio (ANAB) Neutral RecommendationMay 12, 2023 | finanznachrichten.deAnaptysBio, Inc.: AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline UpdateMay 11, 2023 | benzinga.comAnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline UpdateMay 4, 2023 | finance.yahoo.comWall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should KnowMay 2, 2023 | finance.yahoo.comAnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)April 30, 2023 | finance.yahoo.comWhen Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven?April 26, 2023 | finance.yahoo.comWill AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should KnowApril 13, 2023 | msn.comJP Morgan Maintains AnaptysBio (ANAB) Underweight RecommendationSee More Headlines Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Company Calendar Last Earnings8/07/2023Today10/01/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANAB CUSIPN/A CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees96Year Founded2005Price Target and Rating Average Stock Price Forecast$34.75 High Stock Price Forecast$45.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+93.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($5.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-128,720,000.00 Net Margins-1,113.38% Pretax Margin-1,113.19% Return on Equity-65.52% Return on Assets-25.07% Debt Debt-to-Equity RatioN/A Current Ratio10.53 Quick Ratio10.53 Sales & Book Value Annual Sales$10.29 million Price / Sales46.34 Cash FlowN/A Price / Cash FlowN/A Book Value$9.22 per share Price / Book1.95Miscellaneous Outstanding Shares26,550,000Free Float17,122,000Market Cap$476.84 million OptionableOptionable Beta-0.16 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Daniel R. Faga (Age 43)Pres, CEO & Director Comp: $867.12kMr. Eric J. Loumeau (Age 60)Chief Legal Officer Comp: $685.59kDr. James N. Topper M.D. (Age 61)Ph.D., Advisor Comp: $86.5kMr. Hamza Suria M.B.A. (Age 47)M.Sc., Advisory Comp: $3.06MDr. Paul F. Lizzul FAAD (Age 48)M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer Comp: $656.36kMr. Dennis M. Mulroy (Age 68)Chief Financial Officer Mr. Benjamin StoneSr. VP of Corp. Devel.Ms. Beth MuellerSr. VP of HRDr. Martin Dahl Ph.D.Sr. VP of ResearchMr. Douglas A. Rich M.B.A (Age 54)M.B.A., Sr. VP of CMC More ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAHarrow HealthNASDAQ:HROWTheravance BiopharmaNASDAQ:TBPHEntrada TherapeuticsNASDAQ:TRDABiomea FusionNASDAQ:BMEAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 14,308 shares on 9/21/2023Ownership: 0.183%Eric J LoumeauSold 3,895 sharesTotal: $75,251.40 ($19.32/share)Paul F LizzulSold 2,105 sharesTotal: $41,005.40 ($19.48/share)California State Teachers Retirement SystemBought 1,003 shares on 8/21/2023Ownership: 0.089%Nuveen Asset Management LLCSold 3,808 shares on 8/16/2023Ownership: 0.273%View All Insider TransactionsView All Institutional Transactions ANAB Stock - Frequently Asked Questions Should I buy or sell AnaptysBio stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares. View ANAB analyst ratings or view top-rated stocks. What is AnaptysBio's stock price forecast for 2023? 5 analysts have issued 1 year price objectives for AnaptysBio's shares. Their ANAB share price forecasts range from $26.00 to $45.00. On average, they anticipate the company's share price to reach $34.75 in the next twelve months. This suggests a possible upside of 93.5% from the stock's current price. View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts. How have ANAB shares performed in 2023? AnaptysBio's stock was trading at $30.99 at the beginning of 2023. Since then, ANAB stock has decreased by 42.0% and is now trading at $17.96. View the best growth stocks for 2023 here. When is AnaptysBio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ANAB earnings forecast. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. The biotechnology company earned $3.46 million during the quarter, compared to analyst estimates of $5.50 million. AnaptysBio had a negative net margin of 1,113.38% and a negative trailing twelve-month return on equity of 65.52%. What ETF holds AnaptysBio's stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 5,859 shares of ANAB stock, representing 1.01% of its portfolio. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV). When did AnaptysBio IPO? (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is AnaptysBio's stock symbol? AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB." How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AnaptysBio's stock price today? One share of ANAB stock can currently be purchased for approximately $17.96. How much money does AnaptysBio make? AnaptysBio (NASDAQ:ANAB) has a market capitalization of $476.84 million and generates $10.29 million in revenue each year. The biotechnology company earns $-128,720,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. How can I contact AnaptysBio? AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com. This page (NASDAQ:ANAB) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.